Serial Tumor Molecular Profiling of Newly Diagnosed HER2-Negative Breast Cancers During Chemotherapy in Combination with Angiogenesis Inhibitors

ConclusionsSerial molecular profiling identifies early therapy-induced genomic alterations, which may guide future selection of targeted therapies in breast cancer patients who progress after standard chemotherapy.Clinical trial registrationClinicalTrials.gov: NCT02790580 (first posted June 6, 2016).
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research